Adicet Bio, Inc.
LSE: 0HX7.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Brian Nicholas Harvey
- Employees
- 152
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $44.7M
- Website
- https://www.adicetbio.com
Loading 0HX7…
Loading profile data…Frequently asked questions about 0HX7
What does Adicet Bio, Inc. (0HX7.L) do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
Where does 0HX7.L trade?
Adicet Bio, Inc. (0HX7.L) trades on the London Stock Exchange.
What sector is 0HX7.L in?
Adicet Bio, Inc. (0HX7.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Adicet Bio, Inc.?
Brian Nicholas Harvey is the chief executive officer of Adicet Bio, Inc. (0HX7.L).
Where is Adicet Bio, Inc. headquartered?
Adicet Bio, Inc. is headquartered in United States.
Does 0HX7.L pay a dividend?
Adicet Bio, Inc. (0HX7.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HX7.L go public?
Adicet Bio, Inc. (0HX7.L) completed its initial public offering in 2021.